Boston Scientific News
Boston Scientific was a leading decliner within the health services industry, falling $0.10 (-1.0%) to $9.54 on light volume
Boston Scientific initiates clinical trial for its Vercise DBS System in the U.S.
TheStreet Ratings group highlights 4 stocks pushing the health services industry lower today.
Boston Scientific Vercise™ DBS System demonstrates Improvement In Motor Function For Patients With Parkinson's DiseasePR Newswire Jun 18
NATICK, Mass., June 18, 2013 /PRNewswire/ -- Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a significant improvement ...
InPlay: Boston Scientific begins patient enrollment in U.S. clinical trial for use of Cercise DBS system in treatment of Parkinson's diseaseJun 17
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise™ DBS System In Treatment Of Parkinson's DiseasePR Newswire Jun 17
NATICK, Mass., June 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a ...
The markets have hit record highs this year, but these stocks have blown away the device industry.
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
Abbott Labs' Absorb stent features exciting new technology, but is this product ready for the spotlight?